REQUEST FOR INFORMATION

FOR

THE SUPPLY OF ESSENTIAL MEDICINES

Issuance date: 03rd July 2019
Deadline date: 17th July 2019

RFI No: 012019
# TABLE OF CONTENTS

1.0  ABOUT THIS RFI .................................................................................................................. 2
2.0  BACKGROUND OF i+ SOLUTIONS ......................................................................................... 5
3.0  INSTRUCTIONS TO OFFERORS ......................................................................................... 6
4.0  ANNEX A: PHARMACEUTICAL PRODUCT QUESTIONNAIRE .............................................. 8
5.0  ANNEX B: PRODUCT REGISTRATION MATRIX .................................................................... 8
6.0  ANNEX C: BUSINESS AND TECHNICAL INFORMATION SHEET ...................................... 8
7.0  ANNEX D: INDICATIVE PRICE TEMPLATE .......................................................................... 8
1.0 ABOUT THIS RFI

The purpose of this Request For Information (RFI) is to invite manufacturers to provide information requested here in for the supply of a selected range of essential medicines in various strengths and unit of measurements i.e. Co-trimoxazole, Erythromycin (as stearate) and Amoxicillin for use in i+ solution’s global health supply chain programs. Key among such programs is the Global Fund (GF) funded Pooled Procurement Mechanism project.

About the Global Fund

The Global Fund is a 21st-century partnership organization whose major aim is to accelerate the end of HIV, tuberculosis and malaria as epidemics. Founded in 2002, the Global Fund is a leading contributor of resources in the fight against AIDS, tuberculosis and malaria. It mobilizes and invests nearly US$4 billion a year (US$2 billion a year in health products) to support countries and communities most in need. It has an active portfolio of over 430 active grants in over 100 countries, implemented by local experts. See the Global Fund’s website for further information: https://www.theglobalfund.org/en/overview/.

The Global Fund manages the Pooled Procurement Mechanism (PPM) driving the procurement and supply of US$ 1.0 billion health products from and to countries around the world. i+ solutions has been awarded as The Global Funds Procurement Services Agent managing the procurement and supply of Essential Medicines for HIV & TB programs. To support the delivery to Global Fund Principal Recipients under the Pooled Procurement Mechanism i+ solutions would like to invite you to participate in this RFI.

Objective of the RFI

The objective of this RFI is to identify manufacturers of the selected range of essential medicines that;

- Manufacture products that are World Health Organization (WHO) prequalified or Stringent Regulatory Authority (SRA)\(^1\) approved
- Have manufacturing sites that are WHO prequalified or SRA approved
- Are located on the African continent or have plans to establish manufacturing plants on the African continent in the near future
- Have their products registered or filed for registration in selected priority countries that include but are not limited to Malawi, Mozambique, Uganda, Democratic Republic of Congo (DRC), Burundi, Cameroon, Nigeria, Haiti and Gambia
- Offer competitive indicative prices for the selected range of essential medicines

This RFI is issued in order to establish a number of sources that are interested, qualified, and capable of meeting the criteria listed above. The ultimate goal is to establish a short list of

---

\(^1\)Stringent regulatory authorities are defined as countries that participate in the International Conference on Harmonization (ICH). The ICH regulatory authorities include: the U.S. FDA; the Japanese Ministry of Health, Labor and Welfare; the European Agency for the Evaluation of Medicinal Products (EMEA) centralized procedure; and the European Free Trade Area (represented by the Swiss Medic). The Canadian drug regulatory authority, the Therapeutic Products Directorate, Health Canada is also an observer to the ICH and is also considered a stringent drug regulatory authority.
manufacturers that will be invited for a Request For Proposal (RFP) for the supply of the selected essential medicines. The successful vendors from the RFP process will be contracted on a competitive basis contractually to supply these essential medicines in i+ solution’s global health supply chain programs for an initial period of two years subject to extension based on performance.

Manufacturers responding to this RFI should submit a complete;

- Pharmaceutical product questionnaire for each item
- Product registration matrix
- Business and technical information sheet for the organization
- Indicative price template for the selected medicines

### List of selected Essential Medicines

<table>
<thead>
<tr>
<th>S/N</th>
<th>Product description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Co-trimoxazole 800/160mg, Tab 1000 Tabs blister</td>
</tr>
<tr>
<td>2</td>
<td>Co-trimoxazole 800/160mg, Tab 1000 Tabs Jar</td>
</tr>
<tr>
<td>3</td>
<td>Co-trimoxazole 400/80mg, Tab 1000 Tabs blister</td>
</tr>
<tr>
<td>4</td>
<td>Co-trimoxazole 400/80mg, Tab 1000 Tabs Jar</td>
</tr>
<tr>
<td>5</td>
<td>Co-trimoxazole 100/20mg, Dispersible Tab 1000 Tabs blister</td>
</tr>
<tr>
<td>6</td>
<td>Erythromycin (as stearate) 500mg, Tab 100 Tabs blister</td>
</tr>
<tr>
<td>7</td>
<td>Erythromycin (as stearate) 500mg, Tab 500 Tabs Jar</td>
</tr>
<tr>
<td>8</td>
<td>Erythromycin (as stearate) 250mg, Tab 100 Tabs blister</td>
</tr>
<tr>
<td>9</td>
<td>Erythromycin (as stearate) 250mg, Tab 1000 Tabs jar</td>
</tr>
<tr>
<td>10</td>
<td>Amoxicillin 500mg, Caps 1000 Caps Jar</td>
</tr>
<tr>
<td>11</td>
<td>Amoxicillin 500mg, Caps 100 Caps blister</td>
</tr>
</tbody>
</table>

i+ solutions has strong preference for products that are manufactured in Africa that are;

1. Prequalified/approved by WHO or a SRA
2. Manufactured in a facility on a product line that has been prequalified by WHO or approved by a stringent regulatory authority
3. Registered in the selected priority countries that include but are not limited to Malawi, Mozambique, Uganda, Democratic Republic of Congo (DRC), Burundi, Cameroon, Nigeria, Haiti and Gambia
4. Manufactured in accordance with Good Manufacturing Practice (GMP) as certified by a national regulatory authority and/or certified GMP inspectors
5. Manufactured by a firm holding a valid manufacturer’s license for production
6. Comply with standards of current edition of United States Pharmacopeia, or the British, European or International Pharmacopoeias. If the product is not named in any of these publications the products shall be manufactured in accordance with validated in-house specifications, which must be provided to i+ solutions QA department

Note that you are invited to respond to the RFI even if you currently are not in compliance with above requirements but plan to achieve compliance in the near future. Please indicate the timelines of expected approvals in your bid response
Estimated volumes

Estimated volumes for each of the items is provided in the table below to guide manufacturers provide competitive indicative prices.

<table>
<thead>
<tr>
<th>S/N</th>
<th>Product description</th>
<th>UOM</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Co-trimoxazole 800/160mg</td>
<td>1000 Tab Blister</td>
<td>1,065,656</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1000 Tab Jar</td>
<td>457,785</td>
</tr>
<tr>
<td>2</td>
<td>Co-trimoxazole 400/80mg</td>
<td>1000 Tab Blister</td>
<td>225,952</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1000 Tab Jar</td>
<td>673,056</td>
</tr>
<tr>
<td>3</td>
<td>Co-trimoxazole 100/20mg</td>
<td>1000 Dispersible Tab Blister</td>
<td>336,075</td>
</tr>
<tr>
<td>4</td>
<td>Erythromycin (as stearate) 500mg</td>
<td>100 Tab Blister</td>
<td>15,571</td>
</tr>
<tr>
<td></td>
<td></td>
<td>500 Tab Jar</td>
<td>72,174</td>
</tr>
<tr>
<td>5</td>
<td>Erythromycin (as stearate) 250mg</td>
<td>100 Tab Blister</td>
<td>15,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1000 Tab Jar</td>
<td>614</td>
</tr>
<tr>
<td>6</td>
<td>Amoxicillin 500mg</td>
<td>1000 Cap Jar</td>
<td>44,793</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10x10 Cap Blister</td>
<td>6,340</td>
</tr>
</tbody>
</table>

The above estimates are based on records of previous requirements and consumption over the past recent two years. These figures are also based on the most current information available on demand from the respective countries. These estimates are not a representation of the quantities that will actually be required or ordered in the future, or that conditions affecting requirements will be stable or normal.
2.0 BACKGROUND OF i+ SOLUTIONS

i+ solutions is an independent, international, not-for-profit organization specializing in pharmaceutical supply chain management (SCM) in low and middle income countries. It is i+ solutions’ mission to build supply chains that are strong, reliable and ultimately self-sufficient, and support national health systems by using our technical expertise and knowledge. We strive for a world where no medical needs are being unmet.

As a procurement agent, we have a track record of buying high quality, generic medicines at the best possible price. As a supply chain specialist, we support low and middle income countries. Our consultants evaluate loopholes in national health systems and then develop intervention plans, which comprise training programs for healthcare providers, in-house supervision and other capacity-building projects.

i+ solutions is characterized by a multicultural workforce with 56 employees from over 20 countries, representing great diversity in cultural background, country experience, technical and language skills. With extensive experience from within the industry, i+ solutions’ current staff include pharmacists, public health professionals, training experts, procurement specialists, capacity building advisors and logistics specialists.

i+ solutions has its head office in the Netherlands and has a representative office in Nigeria, DRC, Burundi and South Africa. i+ solutions is ISO 9001-2015 certified. This certification covers i+ solutions procurement and supply delivery services as well as technical support on project design, implementation and capacity building for low and middle income countries.

Visit our website for more information: http://www.iplussolutions.org/
3.0 INSTRUCTIONS TO OFFERORS

A. Format
Endeavor to furnish the information requested in the template formats provided in the annexes A to D

B. Costs of offering
Offerors shall bear all costs associated with the preparation and submission of offers, and in no case will i+ solutions be responsible or liable for other costs, regardless of the conduct or outcome of the tendering process.

C. Amendments (including extensions to the due date and time for submission of offers)
At any time prior to the due date and time for the submission of offers, i+ solutions may alter the RFI by issuing written amendments. Any amendment thus issued shall become part of the RFI and will be sent to all known recipients of this RFI. Offerors shall acknowledge receipt of any such amendment in their offer. To give prospective offerors reasonable time in which to take the amendment into account when preparing their offers, i+ solutions may extend the due date and time for submission of offers.

D. Currencies
Prices shall be stated in US dollars ($)

E. Language
The offer as well as the correspondence and documents relating to the offer shall be in English

F. Validity
Offers shall remain valid for 60 days from the due date for receipt of offers. In exceptional circumstances, prior to expiry of the original offer validity period, i+ solutions may request that the offerors extend the period of validity for a specified additional period. Offerors agreeing to the request will not be required to otherwise modify their offer.

G. Timelines
Submission of offers
Offers to this RFI shall be sent electronically by email to tender@iplussolutions.org. The closure date for submission of the offer(s) will be 17th July 2019 CET. Offers received after closure date will NOT be considered. Any Proposal may be modified or withdrawn prior to the deadline. Any modification received after the deadline shall be deemed late and will NOT be considered.

H. Award Process
a) Right to Accept or Reject any or All Offers
   i+ solutions reserves the right to accept or reject any offer, or cancel this entire RFI or part of the RFI and reject all offers at any time without thereby incurring any liability to the affected offeror. Information relating to the examination, clarification, evaluation of responses shall not be disclosed to responders or any other persons not officially concerned with this process.
   Any effort by the responder to influence i+ solutions or any of its employees in the evaluation, bid comparison, may result in the rejection of the offer.

b) Clarification of Offers:
   During evaluation of the offers, i+ solutions may, at its discretion, ask for a clarification of the responses.

c) Successful Offers:
Successful offerors from this RFI process will be invited for the RFP process. i+ solutions will communicate the timelines for the RFP process solely to the shortlisted offerors.

d) Notification to Unsuccessful Offerors

Upon issuance of an award, i+ solutions will promptly notify each unsuccessful offeror. If, after an award is made, Offerors wish to ascertain the grounds on which their offer was not selected, they may address their request to tender@iplussolutions.org within two days after notification.
4.0 ANNEX A: PHARMACEUTICAL PRODUCT QUESTIONNAIRE

5.0 ANNEX B: PRODUCT REGISTRATION MATRIX

6.0 ANNEX C: BUSINESS AND TECHNICAL INFORMATION SHEET

7.0 ANNEX D: INDICATIVE PRICE TEMPLATE